Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Ad-SGE-REIC in unresectable malignant pleural mesothelioma
jRCT2080223982Phase 2Completed
- Sponsor
- Kyorin Pharmaceutical
- Start
- Jul 2018
- Modality
- Adenoviral Vectors → Other Viral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MTG201 in pleural mesothelioma, sponsored by Kyorin Pharmaceutical. Primary endpoint: Progression-free survival (PFS). Started Jul 2018; status: completed.
02
Drugs
MTG201
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on jRCT2080223982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223982.